<DOC>
	<DOCNO>NCT02219646</DOCNO>
	<brief_summary>Given protective effect nitric oxide ( NO ) endothelium result obtain far short-term , continuous treatment phosphodiesterase-5 ( PDE5 ) inhibitors parameter endothelial function , hypothesise chronic treatment vardenafil prevent delay deterioration systemic endothelial function patient type 2 diabetes mellitus . The favourable effect PDE5 inhibitor sexual function patient convincingly demonstrate past . Here hypothesise vardenafil treatment beneficial effect vascular physiology body district , possibly prevent development microangiopathy atherosclerotic cardiovascular disease patient . The main goal study therefore monitor endothelial dysfunction continuous treatment vardenafil 6 month ; object study endothelin 1 know parameter endothelial damage newly diagnose patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Diabetes &amp; Vardenafil</brief_title>
	<detailed_description>Phosphodiesterase-5 ( PDE5 ) inhibitor currently use therapy erectile dysfunction ( ED ) , consider early symptom cardiovascular disease ( CD ) . Impairment endothelial function early lesion precede atherosclerosis common ED , CD vascular complication diabetes mellitus ( DM ) . Continuous administration PDE5 inhibitor tadalafil sildenafil four week men increase cardiovascular risk type 2 DM show improve endothelial function measure flow-mediated dilation reduction inflammatory marker . The goal study investigate whether chronic , long-term treatment vardenafil improve and/or prevents deterioration systemic endothelial function patient type 2 DM . Study design : longitudinal , double-blind , randomised , placebo-controlled interventional study . Patients : 106 male patient ( n determine power analysis ) type 2 DM diagnose classified accord guideline European Association Study Diabetes . Beside antidiabetic treatment , patient randomly assign receive either placebo vardenafil , 10 mg p.o . two time day 24 week . Exclusion criterion : contraindication treatment PDE5 inhibitor . Age range : 40-60 year . Sample size determine power analysis assume variation primary end point ± 10 % baseline 0.05 α level power 80 % , two-sided test dropout rate 15 % . Primary end point : serum endothelin 1 level ( decreased/not increase verum group vs. decrease/increased placebo group ) . Other parameter measurement : Complete clinical workup , weight , height , waist-hip ratio , serum lipid glucose , hemoglobin glycated ( HbA1c ) , micro- macroalbuminuria , homocysteine , high reactive C-protein ( hsCRP ) , interleukin-6 ( IL-6 ) , Tumor necrosis factor ( TNF ) α , fibrinogen , adiponectin , testosterone , sex hormone-binding globulin ( SHBG ) estradiol . All parameter measure baseline , 4 week , 12 week 24 week medication well 4 24 week discontinuation study drug . Study duration : two year . Statistics : descriptive statistic , ANCOVA multiple regression analysis non-parametric test appropriate STATA . Ethics : The trial register . Ethics committee approval patient inform consent obtain . Expected outcome objective : Monitoring endothelial function deterioration type 2 DM chronic administration Vardenafil . Possibility long term-follow study . Publication high impact factor journal .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Male gender Signed write Consent Form Type 2 diabetes mellitus diagnose within 5 year enrolment study Body Mass Index ( BMI ) &lt; 35 ED ( severe , moderate light accord International Index Erectile Function erectile function domain score &lt; 26 ( Rosen et al . 1997 ) ) Age range : 4065 year . Systemic disease except type 2 diabetes mellitus Absence ED Psychiatric disorder All contraindication treatment PDE5 inhibitor , retinitis pigmentosa , nonarteritic anterior ischaemic optic neuropathy , history coronary artery disease , recent myocardial infarction , unstable angina , systemic arterial hypotension , nitricoxide donor therapy , severe hepatic renal failure .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>T2DM</keyword>
	<keyword>ED</keyword>
</DOC>